
https://www.science.org/content/blog-post/sunesis-fails-vosaroxin
# Sunesis Fails with Vosaroxin (October 2014)

## 1. SUMMARY

This brief commentary reports the failure of Sunesis Pharmaceuticals' Phase III VALOR trial for vosaroxin (voreloxin/SNS-595), a quinolone-based drug candidate being tested for leukemia. The article notes that the trial failed to meet its primary endpoint, despite the company's efforts to salvage value from secondary endpoints and potential effects in older patients. The piece references Sunesis's ongoing financial struggles, including previous cost-cutting measures and stock offerings to raise cash, and suggests that the market was not receptive to the company's attempts to find any silver lining in the trial results.

## 2. HISTORY

Following the October 2014 Phase III failure, the vosaroxin development program faced continued setbacks. In January 2015, Sunesis announced it would discontinue the vosaroxin development program entirely and reduce its workforce by approximately 40% to preserve capital. The company shifted its focus to other pipeline assets and explored strategic alternatives.

By 2017, vosaroxin had effectively disappeared from the company's pipeline. Sunesis pivoted to other oncology programs, including vecabrutinib (a BTK inhibitor) for patients with chronic lymphocytic leukemia and other B-cell malignancies. The company continued to face significant financial challenges and underwent multiple restructuring efforts.

In 2021, Sunesis merged with Viracta Therapeutics, effectively ending Sunesis as an independent entity and marking the final chapter for a company whose lead asset had failed decisively years earlier. Vosaroxin did not receive FDA approval and never reached clinical practice for leukemia treatment.

## 3. PREDICTIONS

• **Article's implied prediction**: The market's skepticism toward the company's attempts to highlight secondary endpoints or subgroup effects was accurate. No subsequent regulatory approval or successful commercialization emerged from the vosaroxin data.

• **Wider expectation for quinolone-based oncology drugs**: While vosaroxin specifically failed, the broader class of DNA-intercalating agents and topoisomerase inhibitors has continued to be relevant in oncology, though with mixed success. The failure of vosaroxin did not predict wider failure across the mechanism class.

## 4. INTEREST

Rating: **3/10**

This article documents a fairly typical biotech clinical failure without broader implications beyond the single company involved. While it accurately captured a consequential moment for Sunesis, it lacks broader scientific or industry insights that would give it lasting significance.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20141006-sunesis-fails-vosaroxin.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_